RYTM PRESS-RELEASE SEC Filing Analysis

Latest settled — T+5d

RYTM ▼ -4.90% at T+5d

NEUTRAL call ✗ call lost -4.90% · α vs SPY -4.97% · entry $91.31 → $86.84

Next anchor: T+20d in 5h

Last close $85.93 (close Jun 8) · -5.90% from $91.31 entry

Entry anchored
May 12, 05:53 AM ET
via Databento tick

T+1d

+2.64%

call +2.64% · α +2.06%

$93.72

settled 28d ago

T+5d

-4.90%

call -4.90% · α -4.97%

$86.84

settled 22d ago

T+20d

—

call — · α —

—

in 5h

T+60d

—

call — · α —

—

in 8w

Price Chart

Loading chart...

Executive Summary

Rhythm Pharmaceuticals presented positive clinical data for setmelanotide at ECE 2026, including significant BMI reductions (16.9% at 12 months) and improvements in cardiometabolic risk indices in acquired hypothalamic obesity. The data are encouraging but represent incremental conference presentations rather than a regulatory or financial catalyst.

Actionable Insight

The data support setmelanotide's efficacy but are unlikely to materially change near-term revenue. Monitor for regulatory updates in HO label expansion and upcoming quarterly earnings for prescription trends.

Key Facts

Real-world data showed 16.9% mean BMI reduction at 12 months in acquired HO (n=25, p<0.0001).
Phase 3 TRANSCEND post hoc analysis: metabolic syndrome z-score improved -0.9 vs -0.2 placebo (p<0.0001).
No new safety signals; adverse events consistent with prior Phase 3 trials.
Six posters presented at ECE 2026; none represent regulatory filings or label expansions.

Financial Impact

No financial data provided; impact on revenue is indirect through potential future prescription uptake.

pipelinemarket perception

Risk Factors

Clinical data may not translate to broad commercial adoption.
Competition from other obesity therapies.
Regulatory hurdles for label expansion remain.

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Analyst Consensus

91% bullish (22 analysts)

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

Document	Accession Number
PRESS-RELEASE Data (Synthetic)	press-3292752

8 reports for RYTM

T+1T+5T+20T+60

50% Hit rate 2 of 4 directional calls best @ T+5▲ +15.11%May 1, 2026

Filters

Reports for RYTM — sortable, filterable
	Type				Now
May 26, 2026 14d ago	Press Release NEUTRAL ★ 2/10	$89.82 $87.87	▼ −2.17%	▼ −3.25%	$85.93 (−4.34%)
May 12, 2026 28d ago	Press Release NEUTRAL ★ 4/10	$91.31 $86.84	▼ −4.90%	▼ −4.97%	$85.93 (−5.90%)
May 5, 2026 5w ago	8-K MIXED ★ 6/10	$92.31 $91.31	▼ −1.08%	▼ −3.07%	$85.93 (−6.92%)
May 5, 2026 5w ago	Press Release BULLISH ★ 7/10	$92.31 $91.31	▼ −1.08%	▼ −3.07%	$85.93 (−6.92%)
May 1, 2026 5w ago	Press Release BULLISH ★ 7/10	$81.81 $94.17	▲ +15.11%	▲ +12.76%	$85.93 (+5.03%)
Apr 3, 2026 9w ago	8-K NEUTRAL ★ 3/10	$86.96 $86.81	▼ −0.17%	▼ −4.31%	$85.93 (−1.19%)
Mar 1, 2026 14w ago	Press Release BULLISH ★ 8/10	$94.94 $93.00	▼ −2.04%	▼ −0.84%	$85.93 (−9.50%)
Feb 26, 2026 14w ago	8-K BULLISH ★ 8/10	$98.07 $91.46	▼ −6.74%	▼ −5.61%	$85.93 (−12.38%)

US Market Status

Market Closed — Opens in 6h 58m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access